Validating biomarkers of treatable mechanisms in irritable bowel syndrome

M. Camilleri, Andrea Shin, I. Busciglio, P. Carlson, A. Acosta, A. E. Bharucha, D. Burton, J. Lamsam, A. Lueke, L. J. Donato, A. R. Zinsmeister

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: A valid biomarker is 'an indicator of normal biologic or pathogenic processes, or pharmacological responses to a therapeutic intervention'. There is no validated biomarker for irritable bowel syndrome (IBS). The aim of the study was to assess ability of three quantitative traits to identify treatable processes to discriminate between IBS-diarrhea (IBS-D) patients, IBS-constipation (IBS-C) patients and healthy volunteers (HV). Methods: In 30 HV, 30 IBS-C patients and 64 IBS-D patients, we characterized bowel symptoms and quantitated pathophysiological mechanisms: bile acid (BA) synthesis (serum C4 and FGF19), fecal BA and fat, colonic transit (CT), and intestinal permeability (IP). We used multiple logistic regression and receiver-operating characteristic (ROCAUC) to appraise three factors (fecal BA, CT, and IP) individually and in combination to identify discriminant targets for treatment in IBS. Key Results: There were significant associations between the three subgroups and symptoms reflecting bowel function and the quantitative traits. There were significant associations between fecal BA and CT at 48 h (r = 0.43; p < 0.001) and between fecal BA and IP (r = 0.23; p = 0.015). Individually, fecal BA and CT48 (but not IP) were significant independent predictors for distinguishing HV from IBS. In combination, they discriminated HV from IBS-D patients (ROCAUC 0.70), HV from IBS-C patients (ROCAUC 0.73), and IBS-C patients from IBS-D patients (ROCAUC 0.86). Colonic transit and fecal BA excretion together discriminate between healthy volunteers and IBS-C patients or IBS-D patients, or between the IBS subgroups with 75-90% specificity at 60% sensitivity. Conclusions & Inferences: Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS. We assessed the ability of three quantitative traits to identify treatable processes to discriminate between IBS-D patients, IBS-C patients, and healthy volunteers. Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS.

Original languageEnglish (US)
Pages (from-to)1677-1685
Number of pages9
JournalNeurogastroenterology and Motility
Volume26
Issue number12
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Irritable Bowel Syndrome
Biomarkers
Bile Acids and Salts
Healthy Volunteers
Permeability

Keywords

  • Bile acid
  • Colon
  • Permeability
  • Transit

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Gastroenterology
  • Physiology
  • Medicine(all)

Cite this

Camilleri, M., Shin, A., Busciglio, I., Carlson, P., Acosta, A., Bharucha, A. E., ... Zinsmeister, A. R. (2014). Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterology and Motility, 26(12), 1677-1685. https://doi.org/10.1111/nmo.12421

Validating biomarkers of treatable mechanisms in irritable bowel syndrome. / Camilleri, M.; Shin, Andrea; Busciglio, I.; Carlson, P.; Acosta, A.; Bharucha, A. E.; Burton, D.; Lamsam, J.; Lueke, A.; Donato, L. J.; Zinsmeister, A. R.

In: Neurogastroenterology and Motility, Vol. 26, No. 12, 01.12.2014, p. 1677-1685.

Research output: Contribution to journalArticle

Camilleri, M, Shin, A, Busciglio, I, Carlson, P, Acosta, A, Bharucha, AE, Burton, D, Lamsam, J, Lueke, A, Donato, LJ & Zinsmeister, AR 2014, 'Validating biomarkers of treatable mechanisms in irritable bowel syndrome', Neurogastroenterology and Motility, vol. 26, no. 12, pp. 1677-1685. https://doi.org/10.1111/nmo.12421
Camilleri M, Shin A, Busciglio I, Carlson P, Acosta A, Bharucha AE et al. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterology and Motility. 2014 Dec 1;26(12):1677-1685. https://doi.org/10.1111/nmo.12421
Camilleri, M. ; Shin, Andrea ; Busciglio, I. ; Carlson, P. ; Acosta, A. ; Bharucha, A. E. ; Burton, D. ; Lamsam, J. ; Lueke, A. ; Donato, L. J. ; Zinsmeister, A. R. / Validating biomarkers of treatable mechanisms in irritable bowel syndrome. In: Neurogastroenterology and Motility. 2014 ; Vol. 26, No. 12. pp. 1677-1685.
@article{66a99751b0bf4b23a4d39bd1b1ba28e8,
title = "Validating biomarkers of treatable mechanisms in irritable bowel syndrome",
abstract = "Background: A valid biomarker is 'an indicator of normal biologic or pathogenic processes, or pharmacological responses to a therapeutic intervention'. There is no validated biomarker for irritable bowel syndrome (IBS). The aim of the study was to assess ability of three quantitative traits to identify treatable processes to discriminate between IBS-diarrhea (IBS-D) patients, IBS-constipation (IBS-C) patients and healthy volunteers (HV). Methods: In 30 HV, 30 IBS-C patients and 64 IBS-D patients, we characterized bowel symptoms and quantitated pathophysiological mechanisms: bile acid (BA) synthesis (serum C4 and FGF19), fecal BA and fat, colonic transit (CT), and intestinal permeability (IP). We used multiple logistic regression and receiver-operating characteristic (ROCAUC) to appraise three factors (fecal BA, CT, and IP) individually and in combination to identify discriminant targets for treatment in IBS. Key Results: There were significant associations between the three subgroups and symptoms reflecting bowel function and the quantitative traits. There were significant associations between fecal BA and CT at 48 h (r = 0.43; p < 0.001) and between fecal BA and IP (r = 0.23; p = 0.015). Individually, fecal BA and CT48 (but not IP) were significant independent predictors for distinguishing HV from IBS. In combination, they discriminated HV from IBS-D patients (ROCAUC 0.70), HV from IBS-C patients (ROCAUC 0.73), and IBS-C patients from IBS-D patients (ROCAUC 0.86). Colonic transit and fecal BA excretion together discriminate between healthy volunteers and IBS-C patients or IBS-D patients, or between the IBS subgroups with 75-90{\%} specificity at 60{\%} sensitivity. Conclusions & Inferences: Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS. We assessed the ability of three quantitative traits to identify treatable processes to discriminate between IBS-D patients, IBS-C patients, and healthy volunteers. Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS.",
keywords = "Bile acid, Colon, Permeability, Transit",
author = "M. Camilleri and Andrea Shin and I. Busciglio and P. Carlson and A. Acosta and Bharucha, {A. E.} and D. Burton and J. Lamsam and A. Lueke and Donato, {L. J.} and Zinsmeister, {A. R.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/nmo.12421",
language = "English (US)",
volume = "26",
pages = "1677--1685",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Validating biomarkers of treatable mechanisms in irritable bowel syndrome

AU - Camilleri, M.

AU - Shin, Andrea

AU - Busciglio, I.

AU - Carlson, P.

AU - Acosta, A.

AU - Bharucha, A. E.

AU - Burton, D.

AU - Lamsam, J.

AU - Lueke, A.

AU - Donato, L. J.

AU - Zinsmeister, A. R.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background: A valid biomarker is 'an indicator of normal biologic or pathogenic processes, or pharmacological responses to a therapeutic intervention'. There is no validated biomarker for irritable bowel syndrome (IBS). The aim of the study was to assess ability of three quantitative traits to identify treatable processes to discriminate between IBS-diarrhea (IBS-D) patients, IBS-constipation (IBS-C) patients and healthy volunteers (HV). Methods: In 30 HV, 30 IBS-C patients and 64 IBS-D patients, we characterized bowel symptoms and quantitated pathophysiological mechanisms: bile acid (BA) synthesis (serum C4 and FGF19), fecal BA and fat, colonic transit (CT), and intestinal permeability (IP). We used multiple logistic regression and receiver-operating characteristic (ROCAUC) to appraise three factors (fecal BA, CT, and IP) individually and in combination to identify discriminant targets for treatment in IBS. Key Results: There were significant associations between the three subgroups and symptoms reflecting bowel function and the quantitative traits. There were significant associations between fecal BA and CT at 48 h (r = 0.43; p < 0.001) and between fecal BA and IP (r = 0.23; p = 0.015). Individually, fecal BA and CT48 (but not IP) were significant independent predictors for distinguishing HV from IBS. In combination, they discriminated HV from IBS-D patients (ROCAUC 0.70), HV from IBS-C patients (ROCAUC 0.73), and IBS-C patients from IBS-D patients (ROCAUC 0.86). Colonic transit and fecal BA excretion together discriminate between healthy volunteers and IBS-C patients or IBS-D patients, or between the IBS subgroups with 75-90% specificity at 60% sensitivity. Conclusions & Inferences: Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS. We assessed the ability of three quantitative traits to identify treatable processes to discriminate between IBS-D patients, IBS-C patients, and healthy volunteers. Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS.

AB - Background: A valid biomarker is 'an indicator of normal biologic or pathogenic processes, or pharmacological responses to a therapeutic intervention'. There is no validated biomarker for irritable bowel syndrome (IBS). The aim of the study was to assess ability of three quantitative traits to identify treatable processes to discriminate between IBS-diarrhea (IBS-D) patients, IBS-constipation (IBS-C) patients and healthy volunteers (HV). Methods: In 30 HV, 30 IBS-C patients and 64 IBS-D patients, we characterized bowel symptoms and quantitated pathophysiological mechanisms: bile acid (BA) synthesis (serum C4 and FGF19), fecal BA and fat, colonic transit (CT), and intestinal permeability (IP). We used multiple logistic regression and receiver-operating characteristic (ROCAUC) to appraise three factors (fecal BA, CT, and IP) individually and in combination to identify discriminant targets for treatment in IBS. Key Results: There were significant associations between the three subgroups and symptoms reflecting bowel function and the quantitative traits. There were significant associations between fecal BA and CT at 48 h (r = 0.43; p < 0.001) and between fecal BA and IP (r = 0.23; p = 0.015). Individually, fecal BA and CT48 (but not IP) were significant independent predictors for distinguishing HV from IBS. In combination, they discriminated HV from IBS-D patients (ROCAUC 0.70), HV from IBS-C patients (ROCAUC 0.73), and IBS-C patients from IBS-D patients (ROCAUC 0.86). Colonic transit and fecal BA excretion together discriminate between healthy volunteers and IBS-C patients or IBS-D patients, or between the IBS subgroups with 75-90% specificity at 60% sensitivity. Conclusions & Inferences: Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS. We assessed the ability of three quantitative traits to identify treatable processes to discriminate between IBS-D patients, IBS-C patients, and healthy volunteers. Colonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS.

KW - Bile acid

KW - Colon

KW - Permeability

KW - Transit

UR - http://www.scopus.com/inward/record.url?scp=84911481455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911481455&partnerID=8YFLogxK

U2 - 10.1111/nmo.12421

DO - 10.1111/nmo.12421

M3 - Article

C2 - 25244349

AN - SCOPUS:84911481455

VL - 26

SP - 1677

EP - 1685

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 12

ER -